New proton therapy trial aims to reduce side effects in nasopharyngeal cancer

NCT ID NCT07578727

Not yet recruiting Disease control Sponsor: Guangzhou Concord Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times

Summary

This Phase III trial will compare proton beam radiotherapy with standard photon radiotherapy in 504 patients with non-metastatic nasopharyngeal carcinoma. The goal is to see if proton therapy reduces toxic side effects and improves survival. Participants will be randomly assigned to one of the two radiation types and followed for at least three years.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Proton beam radiotherapy (ProBeam system)
What this could lead to: If successful, proton therapy could become a standard treatment for nasopharyngeal cancer, offering fewer side effects and better survival than current photon radiotherapy.
What could go wrong: This is an early-stage Phase III trial that has not yet started recruiting. Proton therapy is more expensive and less available, and results may not show a clear advantage over existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NASOPHARYNGEAL CARCINOMA (NPC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

nasopharyngeal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NASOPHARYNGEAL CARCINOMA (NPC)

Contacts and locations

Locations

Varian Probeam

Guangzhou, Guangdong, China
Varian Probeam

Guangzhou, Guangdong, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.